IP Library Granted Patent US 7,255,996
Granted Patent B2
US 7,255,996 · App. 11/015,605 · Granted Aug 14, 2007

Compositions, methods and kits for detecting the nucleic acids of HIV-1 and HIV-2

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,255,996
App. No.
11/015,605
Granted
Aug 14, 2007
Kind
B2
Abstract

Compositions, methods and kits for detecting the nucleic acids of HIV-1, HIV-2, or the combination of HIV-1 and HIV-2. Particularly described are oligonucleotides that are useful as hybridization probes and amplification primers, including cross-reacting hybridization probes and cross-reacting amplification primers, for detecting very low levels of viral nucleic acids.

Claims (16)

1. A method of determining whether a test sample contains at least one of HIV-1 nucleic acid and HIV-2 nucleic acid, said method comprising the steps of:

(a) combining said test sample with a pair of cross-reactive primers to form a reaction mixture, wherein said pair of cross-reactive primers is capable of co-amplifying HIV-1 and HIV-2 nucleic acid and comprises a first primer sequence that consists of SEQ ID NO:14, optionally comprising an upstream sequence that is not complementary to either HIV-1 or HIV-2 nucleic acid, and a second primer sequence that consists of SEQ ID NO:7, optionally comprising an upstream sequence that is not complementary to either HIV-1 or HIV-2 nucleic acid;

(b) amplifying, in an in vitro nucleic acid amplification reaction, nucleic acid present in said reaction mixture of step (a); and

(c) detecting in a hybridization reaction an HIV-1 amplicon, an HIV-2 amplicon, or a combination of both amplicons synthesized in step (b), thereby determining that said test sample contains at least one of HIV-1 nucleic acid and HIV-2 nucleic acid.

2. The method of claim 1 , wherein said in vitro nucleic acid amplification reaction in the amplifying step is selected from the group consisting of a Transcription Mediated Amplification (TMA) reaction, a Nucleic Acid Sequence-Based Amplification (NASBA) reaction and a Polymerase Chain Reaction (PCR) reaction.

3. The method of claim 1 , wherein said hybridization reaction in the detecting step comprises a cross-reactive probe which hybridizes independently to said HIV-1 amplicon and to said HIV-2 amplicon.

4. The method of claim 3 , wherein said hybridization reaction in the detecting step further comprises an HIV-1-specific probe which hybridizes only to said HIV-1 amplicon and not to said HIV-2 amplicon.

5. The method of claim 4 , wherein a positive signal indicating hybridization of the cross-reactive probe together with the absence of a positive signal indicating hybridization of the HIV-1-specific probe indicates that said test sample contains HIV-2 nucleic acid and does not contain HIV-1 nucleic acid.

6. The method of claim 3 , further comprising a step for detecting in a hybridization reaction that comprises an HIV-1-specific probe said HIV-1 amplicon without also detecting said HIV-2 amplicon, wherein said HIV-1-specific probe hybridizes only to said HIV-1 amplicon and not to said HIV-2 amplicon.

7. The method of claim 6 , wherein a positive signal indicating hybridization of the cross-reactive probe together with the absence of a positive signal indicating hybridization of the HIV-1-specific probe indicates that said test sample contains HIV-2 nucleic acid and does not contain HIV-1 nucleic acid.

8. The method of claim 3 , wherein said cross-reactive probe is labeled with a homogeneously detectable label.

9. The method of claim 8 , wherein said homogeneously detectable label is a chemiluminescent label.

10. The method of claim 9 , wherein said detecting step comprises detecting with a luminometer.

11. The method of claim 1 , wherein a positive result obtained in said detecting step does not distinguish between said HIV-1 amplicon and said HIV-2 amplicon.

12. The method of claim 1 , wherein said in vitro nucleic acid amplification reaction in the amplifying step is a multiplex amplification reaction that can further amplify, with an assortment of target-specific primers, at least one nucleic acid which is different from HIV-1 and HIV-2.

13. The method of claim 12 , wherein said at least one nucleic acid which is different from HIV-1 and HIV-2 is selected from the group consisting of HBV and HCV.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 16, 2004
From: LINNEN, JEFFREY M.; WU, WEN
To: GEN-PROBE INCORPORATED
Reel/Frame 016113/0652 →